jain.com
The Analysis · Companies · People · Methodology

CEO derivative securities

Company: CoreWeave

This claim was marked delayed on September 4, 2026. Recorded automatically from the cited source when it was published, then queued for evidence review.

How this was decided: Automated extraction from the cited source. The claim is preserved below exactly as it was originally published, so the record shows what was asserted as well as what became of it.

Subject kind
personnel
Statement date
2026-08-22
Promised by
2026-08-20
Promised amount
328207.0 derivative securities
Current status
delayed

The claim, verbatim

CEO Michael Intrator holds 328,207 derivative securities including vested and unvested awards

Source (primary)

CoreWeave CEO Michael Intrator Sold Over 13,000 Shares for $1.2 Million. What Does This Mean for Investors? - Yahoo Finance (-, news_article)
View cached copy (2026-08-31)Live source ↗Archive.org ↗

Quote: “also holds 328,207 derivative securities, including vested and unvested awards”

How we checked this

This claim has not yet been checked assertion-by-assertion against its source. It carries a cited source and quote, but the deeper check has not run. When it does, the result appears here whatever it says.

Additional evidence

confirms CoreWeave CEO Michael Intrator Sold Over 13,000 Shares for $1.2 Million. What Does This Mean for Investors? - Yahoo Finance

Quote: “also holds 328,207 derivative securities, including vested and unvested awards”

View cached copy (2026-08-31)Live source ↗Archive.org ↗

Record of changes

August 31, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
September 1, 2026 — not yet verifiable
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
September 4, 2026 — delayed
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.